Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2016', provides an overview of the Venous Leg Ulcers (Crural ulcer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer) - The report reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Venous Leg Ulcers (Crural ulcer) therapeutics and enlists all their major and minor projects - The report assesses Venous Leg Ulcers (Crural ulcer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Venous Leg Ulcers (Crural ulcer) Overview 7 Therapeutics Development 8 Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Overview 8 Venous Leg Ulcers (Crural ulcer) - Therapeutics under Development by Companies 9 Venous Leg Ulcers (Crural ulcer) - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Venous Leg Ulcers (Crural ulcer) - Products under Development by Companies 13 Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development 14 Adocia 14 CardioVascular BioTherapeutics, Inc. 15 CytoTools AG 16 FirstString Research, Inc. 17 MacroCure Ltd. 18 MediWound Ltd. 19 Pergamum AB 20 RegeneRx Biopharmaceuticals, Inc. 21 Stratatech Corporation 22 Tissue Therapies Limited 23 Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 Biochaperone PDGF-BB - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural ulcer - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 CL-05 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CODA-001 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 CureXcell - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 CVBT-141B - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 EscharEx - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Granexin - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 LL-37 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 RGN-137 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 VF-001 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Venous Leg Ulcers (Crural ulcer) - Recent Pipeline Updates 52 Venous Leg Ulcers (Crural ulcer) - Dormant Projects 59 Venous Leg Ulcers (Crural ulcer) - Discontinued Products 60 Venous Leg Ulcers (Crural ulcer) - Product Development Milestones 61 Featured News & Press Releases 61 Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update 61 Aug 19, 2015: Macrocure Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell in Venous Leg Ulcers 62 Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment 62 Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results 62 Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications 63 May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication 64 Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers 64 Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results 65 Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial 65 Appendix 66 Methodology 66 Coverage 66 Secondary Research 66 Primary Research 66 Expert Panel Validation 66 Contact Us 66 Disclaimer 67
List of Tables
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Venous Leg Ulcers (Crural ulcer) - Pipeline by Adocia, H1 2016 14 Venous Leg Ulcers (Crural ulcer) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2016 15 Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H1 2016 16 Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research, Inc., H1 2016 17 Venous Leg Ulcers (Crural ulcer) - Pipeline by MacroCure Ltd., H1 2016 18 Venous Leg Ulcers (Crural ulcer) - Pipeline by MediWound Ltd., H1 2016 19 Venous Leg Ulcers (Crural ulcer) - Pipeline by Pergamum AB, H1 2016 20 Venous Leg Ulcers (Crural ulcer) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016 21 Venous Leg Ulcers (Crural ulcer) - Pipeline by Stratatech Corporation, H1 2016 22 Venous Leg Ulcers (Crural ulcer) - Pipeline by Tissue Therapies Limited, H1 2016 23 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Stage and Target, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 28 Number of Products by Stage and Route of Administration, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 32 Venous Leg Ulcers (Crural ulcer) Therapeutics - Recent Pipeline Updates, H1 2016 52 Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H1 2016 59 Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H1 2016 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.